Yakira Capital Management Inc. Buys Shares of 23,334 Bausch + Lomb Co. (NYSE:BLCO)

Yakira Capital Management Inc. purchased a new position in shares of Bausch + Lomb Co. (NYSE:BLCO) in the 4th quarter, Holdings Channel reports. The firm purchased 23,334 shares of the company’s stock, valued at approximately $421,000.

Other large investors also recently modified their holdings of the company. Alberta Investment Management Corp increased its holdings in Bausch + Lomb by 36.0% in the 4th quarter. Alberta Investment Management Corp now owns 3,008,193 shares of the company’s stock worth $54,328,000 after purchasing an additional 796,400 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in shares of Bausch + Lomb by 51.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,218,431 shares of the company’s stock worth $21,996,000 after purchasing an additional 414,138 shares during the last quarter. King Street Capital Management L.P. acquired a new position in shares of Bausch + Lomb in the third quarter valued at approximately $14,122,000. Barclays PLC acquired a new position in shares of Bausch + Lomb in the third quarter valued at approximately $5,797,000. Finally, Raymond James Financial Inc. bought a new position in Bausch + Lomb in the 4th quarter valued at approximately $2,844,000. 11.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on BLCO. Wells Fargo & Company reissued an “equal weight” rating and set a $15.00 target price (down from $24.00) on shares of Bausch + Lomb in a report on Friday, March 28th. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Bausch + Lomb in a research note on Tuesday, February 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Bausch + Lomb in a research report on Thursday, February 20th. Royal Bank of Canada cut their target price on Bausch + Lomb from $18.00 to $17.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Stifel Nicolaus decreased their price target on Bausch + Lomb from $17.00 to $15.00 and set a “hold” rating for the company in a research note on Thursday. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $18.82.

Bausch + Lomb Stock Down 7.2 %

Shares of NYSE:BLCO opened at $12.05 on Friday. The business’s 50-day moving average is $15.88 and its 200-day moving average is $17.98. Bausch + Lomb Co. has a 1 year low of $11.94 and a 1 year high of $21.69. The company has a market capitalization of $4.25 billion, a price-to-earnings ratio of -13.24, a P/E/G ratio of 0.85 and a beta of 0.54. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.60 and a quick ratio of 1.01.

Bausch + Lomb (NYSE:BLCO) last issued its quarterly earnings results on Wednesday, February 19th. The company reported $0.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.23 by $0.02. The firm had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.26 billion. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company’s revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.24 earnings per share. Equities research analysts predict that Bausch + Lomb Co. will post 0.74 earnings per share for the current year.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.